Amgen (AMGN) Receives FDA Approval for BLINCYTO sBLA in Ph- r/r ALL
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials.
The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zimmer Biomet Holdings (ZBH) Announces Statistical Superiority in Seven-Year Follow-up of Mobi-C vs. Two-Level ACDF
- Abbott (ABT) Announces Publication of Positive Infant Formula with 2'-FL Human Milk Oligosaccharide+ Data
- Amgen (AMGN) Makes Investment in Israel-Based eHealth Ventures
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesTwitter, Dividend, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!